Scribd
Upload
120 views1 page

Process-Validation - General-Principles-and-Practices-4

This FDA guidance outlines the principles and practices for process validation in the manufacturing of human and animal drugs and biological products. It emphasizes aligning validation activities with a product lifecycle concept and encourages the use of modern pharmaceutical development and quality management systems. The document serves as a framework for manufacturers to ensure compliance with FDA regulations while allowing for alternative approaches if they meet statutory requirements.

Uploaded by

Kendry Jose
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
120 views1 page

Process-Validation - General-Principles-and-Practices-4

This FDA guidance outlines the principles and practices for process validation in the manufacturing of human and animal drugs and biological products. It emphasizes aligning validation activities with a product lifecycle concept and encourages the use of modern pharmaceutical development and quality management systems. The document serves as a framework for manufacturers to ensure compliance with FDA regulations while allowing for alternative approaches if they meet statutory requirements.

Uploaded by

Kendry Jose
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

Guidance for Industry1

Process Validation: General Principles and Practices

This guidance represents the Food and Drug Administration’s (FDA’s) current thinking on this topic. It
does not create or confer any rights for or on any person and does not operate to bind FDA or the public.
You can use an alternative approach if the approach satisfies the requirements of the applicable statutes
and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for
implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate
number listed on the title page of this guidance.

I. INTRODUCTION

This guidance outlines the general principles and approaches that FDA considers appropriate
elements of process validation for the manufacture of human and animal drug and biological
products, including active pharmaceutical ingredients (APIs or drug substances), collectively
referred to in this guidance as drugs or products. This guidance incorporates principles and
approaches that all manufacturers can use to validate manufacturing processes.

This guidance aligns process validation activities with a product lifecycle concept and with
existing FDA guidance, including the FDA/International Conference on Harmonisation (ICH)
guidances for industry, Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and
Q10 Pharmaceutical Quality System. 2 Although this guidance does not repeat the concepts and
principles explained in those guidances, FDA encourages the use of modern pharmaceutical
development concepts, quality risk management, and quality systems at all stages of the
manufacturing process lifecycle.

1
This guidance has been prepared by the Division of Manufacturing and Product Quality, Center for Drug
Evaluation and Research (CDER), in cooperation with CDER’s Office of Pharmaceutical Sciences, the Center for
Biologics Evaluation and Research (CBER), the Office of Regulatory Affairs (ORA) and the Center for Veterinary
Medicine (CVM) at the Food and Drug Administration.
2
To make sure you have the most recent version of a guidance, check the CDER guidance page at
[Link] the CBER guidance
page at
[Link] or
the CVM guidance page at
[Link]
.

You might also like